Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of STNM01 plus nal-IRI/fluorouracil-leucovorin versus nal-IRI/fluorouracil-leucovorin in second-line unresectable pancreatic cancer
jRCT2031240526Phase 3Recruiting
- Sponsor
- TME Therapeutics
- Start
- Dec 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of stnm01 in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by TME Therapeutics. Primary endpoint: Overall survival. Started Dec 2024; status: recruiting.
02
Drugs
stnm01
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031240526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240526.